Quantifying regional hypoxia in human tumors with positron emission tomography of [18F]fluoromisonidazole: A pretherapy study of 37 patients

Janet S. Rasey, Wui Jin Koh, Margaret L. Evans, Lanell M. Peterson, Thomas K. Lewellen, Michael M. Graham, Kenneth Krohn

Research output: Contribution to journalArticle

468 Citations (Scopus)

Abstract

Purpose: To assess pretreatment hypoxia in a variety of tumors using positron emission tomography (PET) after injection of the hypoxia-binding radiopharmaceutical [18F]fluoromisonidazole ([18F]FMISO). Methods and Materials: Tumor fractional hypoxic volume (FHV) was determined in 21 nonsmall cell lung cancer patients, 7 head and neck cancer patients, 4 prostate cancer patients, and 5 patients with other malignancies by quantitative PET imaging after injection of [18F]FMISO (0.1 mCi/kg). The FHV was defined as the proportion of pixels in the intaged tumor volume with a tissue:blood [18F] activity ratio ≤ 1.4 at 120-160 min postinjection. A FHV > 0 was taken as evidence for tumor hypoxia. Results: Hypoxia was observed in 36 of 37 tumors studied with FMISO PET imaging; FHVs ranged from 0 to 94.7%. In nonsmall cell lung cancers (n = 21), the median FHV was 47.6% and the range, 1.3 to 94.7%. There was no correlation between tumor size and FHV. In the seven head and neck carcinomas, the median FHV was 8.8%, with a range from 0.2 to 18.9%. In the group of four prostate cancers, the median and range were 18.2% and 0 to 93.9%, while in a group of five tumors of different types the median FHV was 55.2% (range: 21.4 to 85.8%). Conclusions: Hypoxia was present in 97% of the tumors studied and the extent of hypoxia varied markedly between tumors in the same site or of the same histology. Hypoxia also was distributed heterogeneously between regions within a single tumor. These results are consistent with O2 electrode measures with other types of human tumors. The intra- and intertumor variability indicate the importance of making oxygenation measures in individual tumors and the necessity to sample as much of the tumor volume as possible.

Original languageEnglish (US)
Pages (from-to)417-428
Number of pages12
JournalInternational Journal of Radiation Oncology Biology Physics
Volume36
Issue number2
DOIs
StatePublished - Sep 1 1996
Externally publishedYes

Fingerprint

hypoxia
Positron-Emission Tomography
positrons
tumors
tomography
Neoplasms
cancer
Tumor Burden
Non-Small Cell Lung Carcinoma
Prostatic Neoplasms
fluoromisonidazole
Hypoxia
lungs
Injections
injection
Radiopharmaceuticals
Head and Neck Neoplasms
histology
oxygenation
Histology

Keywords

  • [F]fluoromisonidazole
  • Hypoxia
  • Imaging
  • Positron emission tomography

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiation

Cite this

Quantifying regional hypoxia in human tumors with positron emission tomography of [18F]fluoromisonidazole : A pretherapy study of 37 patients. / Rasey, Janet S.; Koh, Wui Jin; Evans, Margaret L.; Peterson, Lanell M.; Lewellen, Thomas K.; Graham, Michael M.; Krohn, Kenneth.

In: International Journal of Radiation Oncology Biology Physics, Vol. 36, No. 2, 01.09.1996, p. 417-428.

Research output: Contribution to journalArticle

Rasey, Janet S. ; Koh, Wui Jin ; Evans, Margaret L. ; Peterson, Lanell M. ; Lewellen, Thomas K. ; Graham, Michael M. ; Krohn, Kenneth. / Quantifying regional hypoxia in human tumors with positron emission tomography of [18F]fluoromisonidazole : A pretherapy study of 37 patients. In: International Journal of Radiation Oncology Biology Physics. 1996 ; Vol. 36, No. 2. pp. 417-428.
@article{2a98f3e8050f475d8b55ab3391dfb644,
title = "Quantifying regional hypoxia in human tumors with positron emission tomography of [18F]fluoromisonidazole: A pretherapy study of 37 patients",
abstract = "Purpose: To assess pretreatment hypoxia in a variety of tumors using positron emission tomography (PET) after injection of the hypoxia-binding radiopharmaceutical [18F]fluoromisonidazole ([18F]FMISO). Methods and Materials: Tumor fractional hypoxic volume (FHV) was determined in 21 nonsmall cell lung cancer patients, 7 head and neck cancer patients, 4 prostate cancer patients, and 5 patients with other malignancies by quantitative PET imaging after injection of [18F]FMISO (0.1 mCi/kg). The FHV was defined as the proportion of pixels in the intaged tumor volume with a tissue:blood [18F] activity ratio ≤ 1.4 at 120-160 min postinjection. A FHV > 0 was taken as evidence for tumor hypoxia. Results: Hypoxia was observed in 36 of 37 tumors studied with FMISO PET imaging; FHVs ranged from 0 to 94.7{\%}. In nonsmall cell lung cancers (n = 21), the median FHV was 47.6{\%} and the range, 1.3 to 94.7{\%}. There was no correlation between tumor size and FHV. In the seven head and neck carcinomas, the median FHV was 8.8{\%}, with a range from 0.2 to 18.9{\%}. In the group of four prostate cancers, the median and range were 18.2{\%} and 0 to 93.9{\%}, while in a group of five tumors of different types the median FHV was 55.2{\%} (range: 21.4 to 85.8{\%}). Conclusions: Hypoxia was present in 97{\%} of the tumors studied and the extent of hypoxia varied markedly between tumors in the same site or of the same histology. Hypoxia also was distributed heterogeneously between regions within a single tumor. These results are consistent with O2 electrode measures with other types of human tumors. The intra- and intertumor variability indicate the importance of making oxygenation measures in individual tumors and the necessity to sample as much of the tumor volume as possible.",
keywords = "[F]fluoromisonidazole, Hypoxia, Imaging, Positron emission tomography",
author = "Rasey, {Janet S.} and Koh, {Wui Jin} and Evans, {Margaret L.} and Peterson, {Lanell M.} and Lewellen, {Thomas K.} and Graham, {Michael M.} and Kenneth Krohn",
year = "1996",
month = "9",
day = "1",
doi = "10.1016/S0360-3016(96)00325-2",
language = "English (US)",
volume = "36",
pages = "417--428",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Quantifying regional hypoxia in human tumors with positron emission tomography of [18F]fluoromisonidazole

T2 - A pretherapy study of 37 patients

AU - Rasey, Janet S.

AU - Koh, Wui Jin

AU - Evans, Margaret L.

AU - Peterson, Lanell M.

AU - Lewellen, Thomas K.

AU - Graham, Michael M.

AU - Krohn, Kenneth

PY - 1996/9/1

Y1 - 1996/9/1

N2 - Purpose: To assess pretreatment hypoxia in a variety of tumors using positron emission tomography (PET) after injection of the hypoxia-binding radiopharmaceutical [18F]fluoromisonidazole ([18F]FMISO). Methods and Materials: Tumor fractional hypoxic volume (FHV) was determined in 21 nonsmall cell lung cancer patients, 7 head and neck cancer patients, 4 prostate cancer patients, and 5 patients with other malignancies by quantitative PET imaging after injection of [18F]FMISO (0.1 mCi/kg). The FHV was defined as the proportion of pixels in the intaged tumor volume with a tissue:blood [18F] activity ratio ≤ 1.4 at 120-160 min postinjection. A FHV > 0 was taken as evidence for tumor hypoxia. Results: Hypoxia was observed in 36 of 37 tumors studied with FMISO PET imaging; FHVs ranged from 0 to 94.7%. In nonsmall cell lung cancers (n = 21), the median FHV was 47.6% and the range, 1.3 to 94.7%. There was no correlation between tumor size and FHV. In the seven head and neck carcinomas, the median FHV was 8.8%, with a range from 0.2 to 18.9%. In the group of four prostate cancers, the median and range were 18.2% and 0 to 93.9%, while in a group of five tumors of different types the median FHV was 55.2% (range: 21.4 to 85.8%). Conclusions: Hypoxia was present in 97% of the tumors studied and the extent of hypoxia varied markedly between tumors in the same site or of the same histology. Hypoxia also was distributed heterogeneously between regions within a single tumor. These results are consistent with O2 electrode measures with other types of human tumors. The intra- and intertumor variability indicate the importance of making oxygenation measures in individual tumors and the necessity to sample as much of the tumor volume as possible.

AB - Purpose: To assess pretreatment hypoxia in a variety of tumors using positron emission tomography (PET) after injection of the hypoxia-binding radiopharmaceutical [18F]fluoromisonidazole ([18F]FMISO). Methods and Materials: Tumor fractional hypoxic volume (FHV) was determined in 21 nonsmall cell lung cancer patients, 7 head and neck cancer patients, 4 prostate cancer patients, and 5 patients with other malignancies by quantitative PET imaging after injection of [18F]FMISO (0.1 mCi/kg). The FHV was defined as the proportion of pixels in the intaged tumor volume with a tissue:blood [18F] activity ratio ≤ 1.4 at 120-160 min postinjection. A FHV > 0 was taken as evidence for tumor hypoxia. Results: Hypoxia was observed in 36 of 37 tumors studied with FMISO PET imaging; FHVs ranged from 0 to 94.7%. In nonsmall cell lung cancers (n = 21), the median FHV was 47.6% and the range, 1.3 to 94.7%. There was no correlation between tumor size and FHV. In the seven head and neck carcinomas, the median FHV was 8.8%, with a range from 0.2 to 18.9%. In the group of four prostate cancers, the median and range were 18.2% and 0 to 93.9%, while in a group of five tumors of different types the median FHV was 55.2% (range: 21.4 to 85.8%). Conclusions: Hypoxia was present in 97% of the tumors studied and the extent of hypoxia varied markedly between tumors in the same site or of the same histology. Hypoxia also was distributed heterogeneously between regions within a single tumor. These results are consistent with O2 electrode measures with other types of human tumors. The intra- and intertumor variability indicate the importance of making oxygenation measures in individual tumors and the necessity to sample as much of the tumor volume as possible.

KW - [F]fluoromisonidazole

KW - Hypoxia

KW - Imaging

KW - Positron emission tomography

UR - http://www.scopus.com/inward/record.url?scp=0030249455&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030249455&partnerID=8YFLogxK

U2 - 10.1016/S0360-3016(96)00325-2

DO - 10.1016/S0360-3016(96)00325-2

M3 - Article

C2 - 8892467

AN - SCOPUS:0030249455

VL - 36

SP - 417

EP - 428

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 2

ER -